A Prognostic Neural Epigenetic Signature in High-grade Glioma
Overview
Authors
Affiliations
Neural-tumor interactions drive glioma growth as evidenced in preclinical models, but clinical validation is limited. We present an epigenetically defined neural signature of glioblastoma that independently predicts patients' survival. We use reference signatures of neural cells to deconvolve tumor DNA and classify samples into low- or high-neural tumors. High-neural glioblastomas exhibit hypomethylated CpG sites and upregulation of genes associated with synaptic integration. Single-cell transcriptomic analysis reveals a high abundance of malignant stemcell-like cells in high-neural glioblastoma, primarily of the neural lineage. These cells are further classified as neural-progenitor-cell-like, astrocyte-like and oligodendrocyte-progenitor-like, alongside oligodendrocytes and excitatory neurons. In line with these findings, high-neural glioblastoma cells engender neuron-to-glioma synapse formation in vitro and in vivo and show an unfavorable survival after xenografting. In patients, a high-neural signature is associated with decreased overall and progression-free survival. High-neural tumors also exhibit increased functional connectivity in magnetencephalography and resting-state magnet resonance imaging and can be detected via DNA analytes and brain-derived neurotrophic factor in patients' plasma. The prognostic importance of the neural signature was further validated in patients diagnosed with diffuse midline glioma. Our study presents an epigenetically defined malignant neural signature in high-grade gliomas that is prognostically relevant. High-neural gliomas likely require a maximized surgical resection approach for improved outcomes.
Vollmuth P, Karschnia P, Sahm F, Park Y, Ahn S, Jain R Korean J Radiol. 2025; 26(3):246-268.
PMID: 39999966 PMC: 11865903. DOI: 10.3348/kjr.2024.0982.
Liu Z, Jiang H, Kan H, Zhang L, Rao Y, Jiang X J Cell Mol Med. 2025; 29(2):e70362.
PMID: 39833023 PMC: 11745823. DOI: 10.1111/jcmm.70362.
Wood J, Smith S, Castellanos-Uribe M, Lourdusamy A, May S, Barrett D Heliyon. 2025; 11(1):e41309.
PMID: 39816516 PMC: 11732679. DOI: 10.1016/j.heliyon.2024.e41309.
Cancer neuroscience and glioma: clinical implications.
Westphal M, Drexler R, Maire C, Ricklefs F, Lamszus K Acta Neurochir (Wien). 2025; 167(1):2.
PMID: 39752006 PMC: 11698767. DOI: 10.1007/s00701-024-06406-2.
Teske N, Jung L, Teske N, Thon N, Tonn J, Karschnia P Neuro Oncol. 2024; 27(2):583-585.
PMID: 39723569 PMC: 11812044. DOI: 10.1093/neuonc/noae254.